May 9, 2019
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
– IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation – – Data from…
Pharmaceuticals, Biotechnology and Life Sciences
– IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation – – Data from…
DUBLIN–(BUSINESS WIRE)–The “Global Laryngeal Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The laryngeal cancer therapeutics market…
— Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of…
Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc.…
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This…
Increasing visibility of potential study participants to sites and sponsors DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug…
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in…
–Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused…
YCGP’s “With Love, Me” Letters Campaign Brings Together Cancer Survivors and Caregivers to Share Their Heartfelt Personal Stories with Others…
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints…